Dexcom Inc Stock Analysis
| DXCM Stock | USD 70.82 0.81 1.13% |
IPO Date 14th of April 2005 | 200 Day MA 74.2012 | 50 Day MA 68.0166 | Beta 1.488 |
DexCom Inc holds a debt-to-equity ratio of 1.168. At this time, DexCom's Long Term Debt To Capitalization is very stable compared to the past year. As of the 5th of February 2026, Cash Flow To Debt Ratio is likely to grow to 0.36, while Net Debt To EBITDA is likely to drop 1.38. DexCom's financial risk is the risk to DexCom stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
DexCom's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. DexCom's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps DexCom Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect DexCom's stakeholders.
For many companies, including DexCom, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for DexCom Inc, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, DexCom's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 10.2479 | Enterprise Value Ebitda 22.2434 | Price Sales 6.1499 | Shares Float 387.4 M | Wall Street Target Price 85.1923 |
Given that DexCom's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which DexCom is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of DexCom to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, DexCom is said to be less leveraged. If creditors hold a majority of DexCom's assets, the Company is said to be highly leveraged.
At this time, DexCom's Total Stockholder Equity is very stable compared to the past year. As of the 5th of February 2026, Liabilities And Stockholders Equity is likely to grow to about 7.8 B, though Treasury Stock is likely to grow to (176.3 M). . At this time, DexCom's Price Earnings Ratio is very stable compared to the past year. As of the 5th of February 2026, Price Earnings To Growth Ratio is likely to grow to 37.16, while Price To Sales Ratio is likely to drop 8.52. DexCom Inc is undervalued with Real Value of 76.44 and Target Price of 85.19. The main objective of DexCom stock analysis is to determine its intrinsic value, which is an estimate of what DexCom Inc is worth, separate from its market price. There are two main types of DexCom's stock analysis: fundamental analysis and technical analysis.
The DexCom stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. DexCom is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. DexCom Stock trading window is adjusted to America/New York timezone.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. DexCom Stock Analysis Notes
About 97.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 1.0. DexCom Inc had not issued any dividends in recent years. The entity had 4:1 split on the 13th of June 2022. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Dexcom operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 6300 people. To learn more about DexCom Inc call Kevin Sayer at 858 200 0200 or check out https://www.dexcom.com.DexCom Inc Investment Alerts
| DexCom Inc is unlikely to experience financial distress in the next 2 years | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management |
DexCom Largest EPS Surprises
Earnings surprises can significantly impact DexCom's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-04-29 | 2021-03-31 | 0.07 | 0.08 | 0.01 | 14 | ||
2019-07-31 | 2019-06-30 | 0.01 | 0.02 | 0.01 | 100 | ||
2017-08-01 | 2017-06-30 | -0.05 | -0.04 | 0.01 | 20 |
DexCom Environmental, Social, and Governance (ESG) Scores
DexCom's ESG score is a quantitative measure that evaluates DexCom's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of DexCom's operations that may have significant financial implications and affect DexCom's stock price as well as guide investors towards more socially responsible investments.
DexCom Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 5.6 M | Capital Research Global Investors | 2025-06-30 | 5.4 M | Norges Bank | 2025-06-30 | 5.2 M | Amvescap Plc. | 2025-06-30 | 5 M | Amundi | 2025-06-30 | 4.4 M | Groupama Asset Management | 2025-06-30 | 4 M | American Century Companies Inc | 2025-06-30 | 3.9 M | Bank Of New York Mellon Corp | 2025-06-30 | 3.9 M | Northern Trust Corp | 2025-06-30 | 3.8 M | Vanguard Group Inc | 2025-06-30 | 48.3 M | Blackrock Inc | 2025-06-30 | 39 M |
DexCom Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 27.77 B.DexCom Profitablity
The company has Profit Margin (PM) of 0.16 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.2 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.2.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.08 | 0.09 | |
| Return On Capital Employed | 0.15 | 0.16 | |
| Return On Assets | 0.08 | 0.08 | |
| Return On Equity | 0.25 | 0.26 |
Management Efficiency
DexCom Inc has return on total asset (ROA) of 0.0702 % which means that it generated a profit of $0.0702 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3064 %, meaning that it created $0.3064 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 5th of February 2026, Return On Tangible Assets is likely to grow to 0.09. Also, Return On Capital Employed is likely to grow to 0.16. At this time, DexCom's Net Tangible Assets are very stable compared to the past year. As of the 5th of February 2026, Intangible Assets is likely to grow to about 124.9 M, while Debt To Assets are likely to drop 0.40.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.68 | 4.91 | |
| Tangible Book Value Per Share | 4.40 | 4.62 | |
| Enterprise Value Over EBITDA | 31.83 | 33.42 | |
| Price Book Value Ratio | 13.47 | 10.10 | |
| Enterprise Value Multiple | 31.83 | 33.42 | |
| Price Fair Value | 13.47 | 10.10 | |
| Enterprise Value | 220.9 M | 231.9 M |
DexCom showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Technical Drivers
As of the 5th of February, DexCom shows the Downside Deviation of 3.4, coefficient of variation of 2846.98, and Mean Deviation of 1.68. DexCom Inc technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm DexCom Inc jensen alpha, potential upside, as well as the relationship between the Potential Upside and skewness to decide if DexCom Inc is priced favorably, providing market reflects its regular price of 70.82 per share. Given that DexCom has jensen alpha of 0.0475, we urge you to verify DexCom Inc's prevailing market performance to make sure the company can sustain itself at a future point.DexCom Inc Price Movement Analysis
The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Moving Average is predictive technique used to analyze DexCom Inc price data points by creating a series of averages of different subsets of DexCom entire price series.
DexCom Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DexCom insiders, such as employees or executives, is commonly permitted as long as it does not rely on DexCom's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DexCom insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
DexCom Outstanding Bonds
DexCom issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. DexCom Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most DexCom bonds can be classified according to their maturity, which is the date when DexCom Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
DexCom Predictive Daily Indicators
DexCom intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of DexCom stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 170737.0 | |||
| Daily Balance Of Power | (0.46) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 71.39 | |||
| Day Typical Price | 71.2 | |||
| Price Action Indicator | (0.97) | |||
| Period Momentum Indicator | (0.81) |
DexCom Corporate Filings
F4 | 2nd of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 12th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 22nd of December 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 12th of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 10th of November 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 30th of October 2025 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 28th of October 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
DexCom Forecast Models
DexCom's time-series forecasting models are one of many DexCom's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary DexCom's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.DexCom Bond Ratings
DexCom Inc financial ratings play a critical role in determining how much DexCom have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for DexCom's borrowing costs.| Piotroski F Score | 6 | Healthy | View |
| Beneish M Score | (2.69) | Unlikely Manipulator | View |
DexCom Inc Debt to Cash Allocation
Many companies such as DexCom, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
DexCom Inc currently holds 2.59 B in liabilities with Debt to Equity (D/E) ratio of 1.17, which is about average as compared to similar companies. DexCom Inc has a current ratio of 3.69, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about DexCom's use of debt, we should always consider it together with its cash and equity.DexCom Total Assets Over Time
DexCom Assets Financed by Debt
The debt-to-assets ratio shows the degree to which DexCom uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.DexCom Debt Ratio | 40.0 |
DexCom Corporate Bonds Issued
DexCom issues bonds to finance its operations. Corporate bonds make up one of the most significant components of the U.S. bond market and are considered the world's largest securities market. DexCom Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt.
DexCom Net Debt
Net Debt |
|
About DexCom Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how DexCom prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling DexCom shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as DexCom. By using and applying DexCom Stock analysis, traders can create a robust methodology for identifying DexCom entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 0.16 | 0.17 | |
| Operating Profit Margin | 0.13 | 0.14 | |
| Net Profit Margin | 0.13 | 0.14 | |
| Gross Profit Margin | 0.54 | 0.57 |
Current DexCom Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. DexCom analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. DexCom analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 85.19 | Strong Buy | 26 | Odds |
Most DexCom analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand DexCom stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of DexCom Inc, talking to its executives and customers, or listening to DexCom conference calls.
DexCom Stock Analysis Indicators
DexCom Inc stock analysis indicators help investors evaluate how DexCom stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading DexCom shares will generate the highest return on investment. By understating and applying DexCom stock analysis, traders can identify DexCom position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 567.5 M | |
| Long Term Debt | 1.2 B | |
| Common Stock Shares Outstanding | 412.7 M | |
| Total Stockholder Equity | 2.1 B | |
| Total Cashflows From Investing Activities | -207.5 M | |
| Tax Provision | 132.8 M | |
| Quarterly Earnings Growth Y O Y | 1.099 | |
| Property Plant And Equipment Net | 1.4 B | |
| Cash And Short Term Investments | 2.6 B | |
| Cash | 606.1 M | |
| Accounts Payable | 345.3 M | |
| Net Debt | 2 B | |
| 50 Day M A | 68.0166 | |
| Total Current Liabilities | 2.9 B | |
| Other Operating Expenses | 3.4 B | |
| Non Current Assets Total | 2.2 B | |
| Forward Price Earnings | 28.9017 | |
| Non Currrent Assets Other | 53.7 M | |
| Stock Based Compensation | 170.4 M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.099 | Earnings Share 1.8 | Revenue Per Share | Quarterly Revenue Growth 0.216 | Return On Assets |
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value - what DexCom's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.